Clinical Trial Update: BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial of BI 836858 in adults with refractory or relapsed acute myeloid leukemia and in AML in complete remission with high relapse risk;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BI 836858

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Leukemia, Myeloid, Acute | Phase 1 | Status: COMPLETED | Results posted: 2025-01-27